<DOC>
	<DOCNO>NCT02079246</DOCNO>
	<brief_summary>To evaluate long-term safety tolerability idalopirdine ( Lu AE58054 ) adjunctive therapy donepezil patient mild-moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Long-term Safety Tolerability Idalopirdine ( Lu AE58054 ) Adjunctive Treatment Donepezil Patients With Mild-moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This interventional , multi-national , multi-site , open-label extension study patient mild moderate AD complete study 14861A ( NCT01955161 ) 14862A ( NCT02006641 ) . Patients receive 28-weeks treatment idalopirdine 60 mg/day ( option reduce 30 mg/day ) adjunctive treatment donepezil . Approximately 100 patient , complete initial 28-week period , include 24 week open-label treatment period memantine ( sub-study ) evaluate safety tolerability add memantine therapy patient already stable treatment idalopirdine donepezil memantine treatment clinically indicate .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>The patient complete Visit 7 ( Completion Visit ) leadin doubleblind , placebo control clinical study 14861A/NCT01955161 14862A/NCT02006641 . For patient memantine substudy : The patient complete Visit 6 ( Week 28 ) openlabel extension study The patient , accord judgement investigator , require initiation treatment memantine per local label/SmPC/treatment guideline The patient moderate severe ongoing adverse event leadin study consider potential safety risk investigator . The patient experience seizure Completion Visit leadin study . The patient evidence clinically significant disease . The patient 's donepezil treatment likely interrupt discontinue study . The patient receive therapy another acetylcholinesterase inhibitor ( AChEI ) Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>